Dod Michael Joins Thermalin as
Chief Scientific Officer
Cleveland, OH. – May 1, 2018 – Thermalin, Inc., a privately held company with its main laboratories in Cleveland, announced today that Mervyn Dodson (Dod) Michael, Ph.D. has joined the company as its Chief Scientific Officer.
Dr. Michael’s 18-year career at Eli Lilly and Company culminated with his serving as the Senior Director responsible for insulin biology research. Prior to Lilly, Dr. Michael was a post-doctoral fellow at the Joslin Diabetes Center/Harvard Medical School in Boston, MA in Dr. C. Ronald Kahn’s laboratory. He received his Ph.D. from the University of Texas Southwestern Medical Center in Dallas in Cell and Molecular Biology and a B.S. from the University of Alabama.
Michael Weiss, M.D., Ph.D., scientific founder and Chief Innovation Officer of Thermalin, said, “Dr. Michael is a world-class scientist. I am excited to collaborate with him to create revolutionary new therapies for people living with diabetes and other diseases.” Dr. Weiss, who began studying insulin more than 30 years ago as a student in the Harvard-MIT Program in Health Sciences & Technology (HST), recently moved to Indiana University to become Robert A. Harris Professor and Chairman of the Department of Biochemistry & Molecular Biology and Director of Chemical Biology and Biotherapeutics at the Indiana University Precision Health Initiative.
Dr. Michael, who will divide his time between Thermalin’s laboratories in Cleveland and Indianapolis, will work closely with both Dr. Weiss and the Thermalin team. The academic team Dr. Weiss leaves behind at Case Western Reserve University, which includes Prof. Faramarz Ismail-Beigi (Medicine) and Associate Prof. Nelson Phillips (Biochemistry), will also continue to collaborate with Dr. Weiss and Thermalin.
“Dod is a wonderful addition to our team,” said Richard Berenson, Chief Executive Officer of Thermalin. “His deep expertise and experience in insulin biology is the perfect complement to Dr. Weiss’s world-leading knowledge of insulin structure and biophysics. He also brings terrific skills in driving protein drug discovery to successful clinical translation.”
John Brooks, Chairman of the Thermalin Board of Directors and former CEO of the Joslin Diabetes Center in Boston, said “The addition of Dod Michael represents a major milestone for Thermalin and opens the door to accelerated value creation for our current and future partners and investors. He is a great cultural fit who will help us to get the most out of the very strong scientific team at Thermalin and work even more effectively with our collaborators at Sanofi.”
Thermalin is developing next-generation insulin solutions for people with Type 1 (T1D) and Type 2 diabetes (T2D). Thermalin’s preclinical programs include ultra-rapid-acting insulin, insulins that never need refrigeration, glucose-responsive insulin, and a once-a-week insulin patch.
Thermalin’s new molecular designs are the creation of Dr. Michael Weiss and exclusively licensed to Thermalin. Thermalin and Dr. Weiss’s work has been supported by numerous academic and SBIR grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the US NIH (www.niddk.nih.gov). Thermalin and Dr. Weiss have also benefited from generous support from the JDRF (www.jdrf.org). Dr. Weiss gratefully acknowledges additional generous support by the Leona M. and Harry B. Helmsley Charitable Trust (www.helmsleytrust.org).
For more information, please visit www.thermalin.com. For background on insulin therapy for diabetes, please visit www.thermalin.com/background.